share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股东委托书决议
美股SEC公告 ·  2024/09/10 04:31

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the filing of a DEF 14A form with the SEC, scheduling its 2024 Annual Meeting of Stockholders for October 29, 2024. The virtual meeting will invite stockholders to elect a Class II director nominee, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares for the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants. The meeting will also address other business as necessary. The record date for the Annual Meeting is September 4, 2024, with only stockholders of record or their proxies eligible to vote. The company emphasizes the importance of stockholders submitting a proxy to vote their shares prior to the meeting.
ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the filing of a DEF 14A form with the SEC, scheduling its 2024 Annual Meeting of Stockholders for October 29, 2024. The virtual meeting will invite stockholders to elect a Class II director nominee, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares for the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants. The meeting will also address other business as necessary. The record date for the Annual Meeting is September 4, 2024, with only stockholders of record or their proxies eligible to vote. The company emphasizes the importance of stockholders submitting a proxy to vote their shares prior to the meeting.
ZyVersa Therapeutics, Inc. 是一家临床阶段的生物制药公司，宣布向美国证券交易委员会（SEC）提交了一份DEF 14A表格，计划于2024年10月29日召开股东年度大会。这次虚拟会议将邀请股东选举第二类董事提名人，确认Marcum LLP作为独立注册会计师事务所，审批增加2022年全权股权激励计划的股票数量的修正案，并批准在行使特定权证时发行股票。会议还将处理其他业务，如有需要。股东年度大会的登记日期是2024年9月4日，只有名册上的股东或其代理人有资格投票。公司强调股东在会议前提交投票委托以行使其股份的重要性。
ZyVersa Therapeutics, Inc. 是一家临床阶段的生物制药公司，宣布向美国证券交易委员会（SEC）提交了一份DEF 14A表格，计划于2024年10月29日召开股东年度大会。这次虚拟会议将邀请股东选举第二类董事提名人，确认Marcum LLP作为独立注册会计师事务所，审批增加2022年全权股权激励计划的股票数量的修正案，并批准在行使特定权证时发行股票。会议还将处理其他业务，如有需要。股东年度大会的登记日期是2024年9月4日，只有名册上的股东或其代理人有资格投票。公司强调股东在会议前提交投票委托以行使其股份的重要性。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间